Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloi... (rm achieved MMR significantly faster tha...)

HOME >> BIOLOGY >> TECHNOLOGY

Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia

Date:6/13/2008

rm achieved MMR significantly faster than those who started treatment with Gleevec at 400 mg(1). Achievement of a MMR is an important goal of therapy for CML.

"TOPS reaffirms Gleevec as the standard of care for newly diagnosed CML patients," said Jorge Cortes, MD, Professor of Medicine and Deputy Chair of Leukemia at the University of Texas MD Anderson Cancer Center in Houston. "We see a strong trend for rapid response with the 800 mg dose. As with trials like IRIS, further follow up will be needed to assess what this rapid early response will mean in terms of long-term benefit."

TOPS also showed that patients with lower blood levels of Gleevec at one month had a lower molecular response at a year, an observation made in previous studies(2). Cumulatively, these data suggest that maintaining adequate blood levels may help attain better clinical responses(2).

These findings, from the first analysis of the TOPS data set, will be presented on Saturday, June 14, at the 2008 Congress of the European Hematology Association (EHA) in Copenhagen.

"Our robust clinical program with Gleevec continues to provide meaningful insights into the treatment of Ph+ CML and other types of cancer," said Diane Young, MD, Head of Global Medical Affairs at Novartis Oncology. "Novartis continues to invest in trials like ENESTnd, which is comparing Tasigna to Gleevec in the first-line setting, to build on this knowledge and further enhance treatment outcomes for patients."

ENESTnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials of newly diagnosed Ph+ CML patients) is designed to study the efficacy and safety of Tasigna(R) (nilotinib) capsules vs. Gleevec in newly diagnosed patients in the chronic phase. ENESTnd is currently underway and will enroll approximately 771 patients at 220 centers worldwide. Tasigna is currently approved for the treatment of Ph+ CML in the chronic or accelerated phase in patients resistant to, or intolerant of, Gleevec. <
'/>"/>

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related biology technology :

1. Video: Data From 185,000 ICU Admissions Show Significant Reductions in Mortality:
2. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
3. Video: Trinity Mother Frances Neurosurgeon Using New Disc System for Patients With Degenerative Diseases of the Neck
4. Major Medical Journal Reports Higher Success, Fewer Complications and Lower Cost Treating DVT With Trellis(R) Isolated Thrombolysis Compared With Catheter-Directed Thrombolysis
5. ChemAxon Launches Marvin and JChem Version 5: Better User Experience, Better Integration, More Flexibility and Higher Performance
6. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
7. Notice of Initial Distribution of Net Settlement Funds
8. Awareness of Genzymes Renvela(R) (Sevelamer Carbonate) is High, Although Uptake of this New Phosphate Binding Agent has Been Slower than Nephrologists and Renal Dietitians Initially Expected
9. QLT reports initial proof of concept data for punctal plug delivery technology
10. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
11. Ferring Initial Purchase Order and Guaranteed Letter of Credit Launches Five Year Contract

Post Your Comments:

Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloi...(rm achieved MMR significantly faster tha...)